"Terminal elimination half-life = 50 hours "@en . "223673-61-8"@en . . "When taken with meals, levels of mirabegron decreased. Furthermore, the magnitude of this effect was greater if taken with a low fat meal, rather than a high fat meal. Despite these findings, dose adjustment is not required."@en . . . . . . . . . . . . "71% bound to plasma proteins. It binds to albumin and alpha-1-acid glycoprotein with moderate affinity. "@en . . "Vd, steady state, IV dose = 1670 L. This high value suggests that mirabegron is extensively distributed in the body. "@en . . . . "Mirabegron is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency."@en . . . . . . . . "Mirabegron is a beta-3 adrenergic receptor agonist for the management of overactive bladder. It is an alternative to antimuscarinic drugs for this indication. FDA approved on June 28, 2012. "@en . "Mirabegron is eliminated via urine (radiolabeled drug: 55%; unchanged drug: ~25%) and feces (radiolabeled drug: 34%; unchanged drug: 0%). Renal elimination of mirabegron is primarily through active tubular secretion and glomerular filtration. Extent of elimination via urine is dose-dependent. "@en . . . . . "# FDA label # Kashyap M, Tyagi P: The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option. Expert Opin Drug Metab Toxicol. 2013 May;9(5):617-27. doi: 10.1517/17425255.2013.786700. Epub 2013 Apr 4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/23550899"@en . "Myrbetriq"@en . . . . . . . . . . . . "Humans and other mammals"@en . . . . "Total body clearance (CLtot), IV dose = 57 L/h; Renal clearance (CLR) = 13 L/h"@en . . . "approved"@en . . " "@en . "The absolute bioavailability increases from 29% at a dose of 25 mg to 35% at a dose of 50 mg. Mean Cmax and AUC increase more than dose proportionally. This relationship is more apparent at doses above 50 mg. Females generally have a lower magnitude of increase of Cmax and AUCtau compared to males when doses of mirabegron doubles or quadruples. Steady state concentrations are achieved within 7 days of once daily dosing with mirabegron. After once daily administration, plasma exposure of mirabegron at steady state is approximately double that seen after a single dose. Tmax, oral dose, healthy subjects= 3.5 hours;"@en . "Mirabegron"@en . "Most commonly reported adverse reactions (> 2% and > placebo) were hypertension, nasopharyngitis, urinary tract infection and headache"@en . . "Mirabegron is a potent and selective agonist for beta-3 adrenergic receptors. Once beta-3 receptors are activated, the detrusor smooth muscle relaxes to allow for a larger bladder capacity. At higher doses (200 mg), there is a potential for mirabegron to activate beta-1 and beta-2 adrenergic receptors. "@en .